A significant vote of confidence from Wall Street has turned heads back toward Micron Technology NASDAQ: MU. Morgan Stanley recently boosted its price target on the memory chip maker to a remarkable $338, reinforcing its Overweight rating and signaling conviction in the stock's continued ascent.
I maintain a hold rating on Astria Therapeutics with an updated $13 target price following Biocryst's announced acquisition, expecting a 90%+ chance of deal closure by Q1 2026. The investment thesis shifts from clinical catalyst to merger arbitrage, with strong strategic rationale for BCRX to acquire ATXS and minimal regulatory or financial barriers anticipated. Navenibart (STAR-0215) is viewed as a best-in-class prophylaxis agent, and the acquisition offers shareholders a liquidity event, mitigating phase 3 and competitive risks.
Target Corporation (TGT) faces ongoing operational challenges, weak free cash flow, and a high debt load, putting its 57-year dividend streak at risk. TGT's core discretionary categories are in decline, with growth limited to lower-margin food and essentials, reflecting cautious consumer behavior and structural margin pressure. Rising Capex commitments and a dividend funding gap threaten the sustainability of TGT's payout, with management signaling no near-term turnaround in business dynamics.
Brands are vying for the billions Americans are expected to spend the day after Thanksgiving.
Target announced a $5 billion investment to expand with larger stores and revamp existing locations despite ongoing sales challenges and market pressures.
Semiconductor stock Applied Materials Inc (NASDAQ:AMAT) is up 1.7% to trade at $235.81 at last check, on the heels of an upgrade to "buy" from "neutral" at UBS.
TGT's new Gen-AI Gift Finder and upcoming ChatGPT shopping aim to boost digital engagement and drive its next growth phase.
Target (TGT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
BMO analyst Raj Ray upgraded shares of MP to Buy from Hold. His price target went down $1 to $75 a share.
Target (TGT) and Walmart (WMT) offered insight into the strength of the consumer in their Q3 reports this week, and both were able to pleasantly beat earnings expectations.
TGT's third-quarter results reveal soft demand, shrinking margins and a sliding stock, prompting investors to reassess the retailer's turnaround prospects.
Target NYSE: TGT is trading in deep-value territory, offering a projected 5% dividend yield in late 2025, but that alone may not be enough reason to buy in. Despite some potential for recovery in 2026, near-term headwinds remain strong.